🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise around the world, with data suggesting in excess of 82 million infections per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to license and sell the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared positive views. Having a one-pill regimen like this is described as a "game-changer" for public health efforts. This is deemed vital to lessen the impact of the illness for people and to halt the transmission of extremely resistant gonorrhoea worldwide.